TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00877903
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of excipients of Prochymal®
Study: NCT03283696
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered IV
Study: NCT00332605
Drug: Naltrexone plus N-Acetyl Cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily
Study: NCT00332605
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily
Study: NCT01309243
Drug: FTC/RPV/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (TDF) 300 mg single-tablet regimen administered orally once daily with a meal
Study: NCT01309243
Drug: EFV/FTC/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz (EFV) 600 mg/FTC 200 mg/TDF 300 mg single-tablet regimen administered orally once daily on an empty stomach, preferably at bedtime
Study: NCT02779283
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02779283
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00002802
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002802
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02779283
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02779283
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00545363
Drug: Ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive ibandronate 150 mg QM orally for 6 months.
Study: NCT00062686
Drug: GW572016
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01141270
Drug: AFOLIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: single sc injection, 225 IU
Study: NCT01850823
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03009019
Drug: DFN-15 Active
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03248141
Drug: Hemophilia A standard half-life
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xyntha and other standard half-life agents
Study: NCT03248141
Drug: Hemophilia A extended half-life
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eloctate and Adynovate
Study: NCT02194842
Drug: Ra223
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02248636
Drug: Cholinesterase inhibitor
Normalized name: Acetylcholinesterase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group receives a half-dose of their previous cholinesterase inhibitor medication (in overencapsulated form) for two weeks, then receives placebo.
Study: NCT03034057
Drug: Sayana Press
Normalized name: garden cress sprout extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sayana Press in the Uniject injection system
Study: NCT02248636
Drug: Sham discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group receives their previous dose of cholinesterase inhibitor medication, but in overencapsulated form
Study: NCT02562950
Drug: GLPG1837 500 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive multiple oral daily doses of GLPG1837 (250 mg b.i.d. for 11 days) from Days 2 to 12.
Study: NCT02562950
Drug: GLPG1837 1000 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive multiple oral doses of GLPG1837 (500 mg b.i.d. for 11 days) from Days 2 to 12.
Study: NCT04839549
Drug: Dextenza 0.4Mg Ophthalmic Insert
Normalized name: Dextenza 0.4mg Ophthalmic Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextenza 0.4Mg Ophthalmic Insert
Study: NCT04839549
Drug: Fluoromethalone .01%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoromethalone .01%
Study: NCT01814826
Drug: MLN4924
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLN4924 intravenously (IV) in AML participants in a 28-day cycle:~* MLN4924 on Days 1, 3, and 5 for Cycle 1 and all subsequent cycles
Study: NCT00533624
Drug: Mycophenolate Sodium Delayed Release Tablets
Normalized name: mycophenolic acid Delayed Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myfortic® 1,440 mg/day
Study: NCT04848181
Drug: no treatment received
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: no treatment received before TURP
Study: NCT03342118
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group was treated with normal saline before endoscopy
Study: NCT00899379
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to Rizatriptan, Oral Tablet
Study: NCT04151706
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/kg/dose Q24h IV. Infused over 2 hours. 1 dose per day x 2 consecutive days x 60 mg/kg/dose = 120 mg/kg
Study: NCT00212277
Drug: Norethindrone,Ethinyl Estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03176446
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine with epinephrine 1: 100000 1.8 mL
Study: NCT01503983
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine: 1000 mg/m2/12h/days 1 - 14 every 3 weeks (v.o.)
Study: NCT01837290
Drug: saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion to facilitate blinding
Study: NCT03375632
Drug: FYU-981
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral daily dosing for 14 weeks
Study: NCT03375814
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: The group that takes Placebo Oral Tablet. They received the conventional treatment and Placebo Pills..
Study: NCT00986115
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After a two-month prospective baseline during which seizure frequency and neurocognitive parameters are documented, patients will be randomized to either memantine or placebo and evaluated after twelve months on study drug. The treatment period will consist of a one month dose escalation phase, followed by an eleven month maintenance phase. The dose escalation is 5 mg in PM for days 1-7, 5 mg twice daily for days 8-14, 5 mg in AM and 10 mg in PM for days 15-21 and 10 mg twice daily from day 22 and continue.
Study: NCT04575675
Drug: Beta blocker
Normalized name: Beta blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardio-selective beta-blocker, including carvedilol, bisoprolol, metoprolol or nebivolol
Study: NCT05181943
Drug: Conventional symptomatic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment using oracure, BBC spray, miconaz three times daily
Study: NCT00309920
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00309920
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00309920
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003185
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02467413
Drug: BAC
Normalized name: Bacid
Approvals — FDA: no, EMA: no, PMDA: no
Description: (vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof)
Study: NCT00637832
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00637832
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00637832
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01767129
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule twice daily for 14 days
Study: NCT01110720
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Nasal Spray BID IN 52 weeks
Study: NCT02154477
Drug: placebo (intranasal saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline
Study: NCT01172639
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate tablet
Study: NCT01037413
Drug: EXC 001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple intradermal injections of EXC 001 and placebo
Study: NCT01037413
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple intradermal injections of EXC 001 and placebo
Study: NCT00809341
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m\^2 on Day 1 of each cycle as part of R-CHOP.
Study: NCT00809341
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m\^2 on Day 1 of each cycle as part of R-CHOP.
Study: NCT00809341
Drug: High-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/kg/day on Days 2-5 of HiCy.
Study: NCT00237614
Drug: intravenous and oral N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01843452
Drug: CAPECITABINE
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 825mg/m2 orally twice daily on study days 1 through 45.
Study: NCT01487902
Drug: ADT
Normalized name: Radtue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luprolide 11.25 mg long-acting depo (Lucrin Depot PDS inj®) every 12 weeks SC wit Docetaxel-prednisolone (TAX327 regimen)
Study: NCT01487902
Drug: No ADT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel-prednisolone (TAX327 regimen) alone
Study: NCT02477449
Drug: 9% Saline (NS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: infusion for 24 hours
Study: NCT02125136
Drug: Gem/nab-Pac
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patient receive:~2 cycles gemcitabine/nab-paclitaxel (\[Gem/nab-Pac\]; duration of each cycle 28 days)~Then:~Nab-paclitaxel 125 mg/m2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m2 as a 30-minute IV infusion on D1, D8, D15 of each 28-day cycle
Study: NCT02125136
Drug: FOLFIFINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patient receive:~2 cycles gemcitabine/nab-paclitaxel (\[Gem/nab-Pac\]; duration of each cycle 28 days)~Then:~Oxaliplatin 85 mg/m2, given as a 2-hour intravenous infusion D1 Folinic acid 400 mg/m2, given as a 2-hour intravenous infusion D1 Irinotecan 180 mg/m2, given as a 90-minutes intravenous infusion D1 (application through a Y-connector parallel to infusion of folinic acid or 30 minutes after start of folinic acid possible) Fluorouracil 400 mg/m2, administered by intravenous bolus, followed by a continuous intravenous infusion of fluorouracil 2400 mg/m2 over a 46-hour period D1.~To be repeated on D1 of each cycle.
Study: NCT00702416
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 µg iv prn (in the intraoperative period)
Study: NCT01650519
Drug: IV ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 mg intravenous ibuprofen administered intravenously over 10 minutes.
Study: NCT00616746
Drug: Ethanol
Normalized name: Ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV
Study: NCT01876771
Drug: [177]Lu-DOTA-TATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide receptor radionuclide therapy (PPRT)
Study: NCT01412632
Drug: Remifentanil, propofol and citanest
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv remifentanil iv propofol im citanest
Study: NCT04402203
Drug: Only Standard Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment included oxygen inhalation, oral or intravenous rehydration, electrolyte correction, antipyretics, analgesics, antibiotics and antiemetic drugs \& the medication any patient is on due to any concomitant diseases.
Study: NCT00944892
Drug: REGN475
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 Administrations of REGN475 within 24 weeks.
Study: NCT04023149
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: placebo; Pharmaceutical form: solution; Route of administration: oral gargle.
Study: NCT02348372
Drug: GSK1278863A Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching size, shape and color
Study: NCT02348372
Drug: GSK1278863A
Approvals — FDA: no, EMA: no, PMDA: no
Description: A round, biconvex, white film coated tablet
Study: NCT02901145
Drug: Nivolumab,low dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment with IV Nivolumab 3mg/kg every 2 weeks . after a month-addition of low dose cyclophosphamide at a starting dose of 50 mg/kg/day x7 days every 14 days with dose adaptation based on level of Tregulatory cells on follow up immunophenotype.
Study: NCT02633397
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to riociguat 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg three times a day for 12 weeks
Study: NCT02275299
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 2.5 mg/tablet, taken orally once a week, 4 tablets/week,52 weeks
Study: NCT00547183
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet taken by mouth once a day, no more than 1 dose per day, for 12 weeks
Study: NCT00632008
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of placebo to wound, at least twice a week until compleate healing or for maximum 8 weeks.
Study: NCT02480751
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04596826
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT03666884
Drug: COE 2*1 (Restasis) + PFAT Refresh Single dose) 8*1
Approvals — FDA: no, EMA: no, PMDA: no
Description: clinical improvement in oxford scale, ocular surface disease index, schirmers test, tear break up time, fluorescein staining of eye
Study: NCT02874651
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take oral placebo. The initial dose is 500 mg once daily. 28 days as one cycle. After 1 cycle, the dose will be escalated to 750 mg once daily in patients with good tolerance. Dose interruption or reduction is permitted in case of adverse events per protocol.
Study: NCT01824433
Drug: fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fluoxetine 20-60mg qd
Study: NCT04596033
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lymphodepletion drug
Study: NCT00344422
Drug: Vincristine, DOXIL (doxorubicin HCl liposomal injection), and Dexamethasone (VDD) vs. Vincristine, Doxorubicin and Dexamethasone (VAD)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00494208
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone ester
Study: NCT02859441
Drug: E10030
Approvals — FDA: no, EMA: no, PMDA: no
Description: E10030 is not a commercially available drug product, and will be provided by Ophthotech Corp. The drug product is provided as a sterile aqueous solution of E10030 at a concentration of 30 mg (oligo weight)/mL. The solution contains monobasic sodium phosphate monohydrate and dibasic sodium phosphate heptahydrate as buffering agents as well as sodium chloride as a tonicity adjuster. The intravitreal injection volume of E10030 is 50 microliter, which correlates to 1.5 mg of dry E10030.
Study: NCT00371852
Drug: lactoserum
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04236739
Drug: Instant MSC Product accompanying Autologous Chondron Transplantation
Normalized name: Advanced Eye Relief Redness Instant Relief Ophthalmic Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of a mixture of allogenic MSC's and autologous chondrons with a fibrin cell carrier (Tisseel®) in the cartilage defect of the knee during one surgical procedure.
Study: NCT00005969
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00005969
Drug: Tretinoin Liposome
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposome by vein (IV) over 30 minutes every other day for 28 days
Study: NCT00331955
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03972397
Drug: Patient-controlled analgesia (PCA)
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will have access to the standard PCA (Patient-Controlled Analgesia) offered at the Memorial Hermann Hospital - Texas Medical Center. The PCA drug will be Dilaudid (hydromorphone). Initial dosing will be per the standard hospital protocol of 0.2 mg demand dose, 10-minute lockout, 2 mg per hour max, 0.4 mg rescue dose. Adjustments to the PCA dosing will be made based on clinical needs.
Study: NCT01315444
Drug: Stop PPI gradually
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01538225
Drug: Sativex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC:CBD 1:1 ratio oromucosal spray. A titration period is required to reach optimal dose. The number and timing of sprays may vary between patients.~Duration: 2 weeks
Study: NCT01538225
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo~Same frequency and dosage form as Sativex.~Duration: 2 weeks
Study: NCT02562859
Drug: 500 mg GLPG1837 as oral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 500 mg GLPG1837 administered as oral suspension
Study: NCT02562859
Drug: 500 mg GLPG1837 as oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 500 mg GLPG1837 administered as oral tablet
Study: NCT00092326
Drug: MK0966, rofecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01669083
Drug: GSK557296 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg single oral dose. Each subject will receive 2 tablets of 5 mg GSK557296 four times a day (QID).
Study: NCT00799747
Drug: AZD4017
Approvals — FDA: no, EMA: no, PMDA: no
Description: ascending single doses (start dose 2 mg), oral suspension
Study: NCT01669083
Drug: GSK557296 150 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg single oral dose. Each subject will receive multiple tablets of 25 mg GSK557296 either 2, 3 or 4 times a day.
Study: NCT01669083
Drug: GSK557296 dose 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose to be determined as a single dose tablet based on half-life demonstrated in Cohort 1 and Cohort 2.
Study: NCT01669083
Drug: GSK557296 dose 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose to be determined by PK of prior doses, based on half-life demonstrated in prior cohorts.
Study: NCT00799747
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00309270
Drug: Campath-1H
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01618695
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Core study: Week 0 to Week 18 Once daily placebo.~Extension study:~Week 19 to Week 22 Once daily placebo, Week 23 Once daily perampanel 2 mg/day, Week 24 Once daily perampanel 4 mg/day, Week 25 Once daily perampanel 6 mg/day, Week 26 Once daily perampanel 8 mg/day, Week 27 Once daily perampanel 10 mg/day, Week 28 to Week 75 or more Once daily perampanel 12 mg/day.
Study: NCT02705625
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo manufactured to mimic MIV-711 capsule.
Study: NCT03347266
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: water for injection
Study: NCT02943707
Drug: drugs such as Ursodeoxycholic Acid tablets
Normalized name: ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic Acid tablets(UDCA), each time 150 mg, three times a day orally
Study: NCT04150341
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will be administered by inhalation in the morning for 14 days during each period. A washout period of at least 21 days will exist between subsequent periods.
Study: NCT04346446
Drug: Convalescent Plasma Transfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent Plasma Transfusion
Study: NCT01649297
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive placebo matching empagliflozin (low dose qd)
Study: NCT01649297
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive placebo matching empagliflozin (low dose bid)
Study: NCT01649297
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive placebo matching Empagliflozin (high dose qd)
Study: NCT01649297
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive placebo matching Empagliflozin (high dose bid)
Study: NCT02243735
Drug: ferric(III)carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients randomized to intravenous iron (ferric(III)carboxymaltose) will be dosed according to Summary of Product Characteristics (SPC) depending on body weight and Hb value and administered in one or two infusions with one week in between. A maximum dose of 1000mg or 15mg/kg per week will be administered
Study: NCT02648711
Drug: CRLX101
Approvals — FDA: no, EMA: no, PMDA: no
Description: infusion CRLX101 weekly
Study: NCT00358436
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once-daily via inhalation: 1 puff in the morning for 52 weeks